John Nolan Joins WBB to Head Asset Management Team
For Immediate Release
September 2, 2016
SAN DIEGO, CA – WBB Securities, a leading investment management, investment banking, and equity research firm, announced today that John Nolan has joined the firm as Managing Director of WBB Asset Management where he will also serve as a Portfolio Manager of a concentrated long/short portfolio that focuses on the biotechnology, specialty pharmaceutical and medical device sectors. The strategy is slated to launch in January 2017.
Mr. Nolan joins WBB from JPMorgan Chase where he served as Vice President and Co-Head of Quantitative Investment Research (QIR) for Manager Selection. In his role at JPMorgan, Mr. Nolan was responsible for performing investment due diligence on internal and external managers across the firm’s wealth management platforms. With coverage of over forty managers across US equity sub-asset classes and specialty coverage of healthcare-focused strategies, Mr. Nolan was responsible for approximately $5 billion in Assets Under Management. In his role as Co-Head of QIR he developed novel quantitative approaches to assessing portfolio performance with particular emphasis on disaggregating skill from luck and portfolio factor exposures.
Before JPMorgan, Mr. Nolan held a similar role at Barclays Wealth Management. In addition to his time on Wall Street, Mr. Nolan spent several years as a researcher and epidemiologist at various medical institutions including the University of Pennsylvania Perelman School of Medicine and the NYU Langone School of Medicine. He has been published in peer-reviewed journals on topics ranging from environmental toxicology to hepatitis B infection in children.
“We are delighted to have John join our team as we seek to expand the capabilities and functions of our investment bank,” said Steve Brozak, Managing Partner of WBB. “John is highly respected in both the financial and medical communities for his knowledge and keen insights in the biotechnology and healthcare sectors. In keeping with the innovative and differentiated approach of WBB, we welcome the perspective he brings to our firm and to our institutional clients seeking the best options for their investments.”
Mr. Nolan holds a MPH degree from Johns Hopkins Bloomberg School of Public Health and a bachelor’s degree in Physics and History from Cornell University.
WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients.
WBB Asset Management is the investment management arm of WBB Securities. WBB Asset Management leverages the proprietary research and analytics developed at the firm to identify and invest in emerging life science companies with potentially disruptive technologies. Investors in the firm’s strategies benefit from the knowledge and expertise gained over decades of diligence within the biotech sector. The asset management division offers a series of strategies in the life sciences for potential institutional investors.
The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. Our investment bank has participated in over 120 transactions leading to $4 billion placed. Whether raising capital or executing strategic transactions, our banking team is equipped to meet your financial needs and is comprised of some of the most knowledgeable people working in the life sciences domain. For more information, please visit www.wbbsec.com.
 WBB Asset Management is provided through WBB Securities, LLC, a Registered Investment Advisor.